Remoxipride

Porphyria. Comatose states, CNS depression, phaeochromocytoma, lactation, history of blood disorders.

Hepatic impairment, renal impairment, CV disease, Parkinson's disease, epilepsy, depression, myasthenia gravis, prostatic hypertrophy, severe respiratory disease, blood dyscrasias, history of jaundice. Elderly. May affect driving, especially during the initial part of the treatment. Pregnancy.

Extrapyramidal effects in neonates have been reported. Parkinsonian symptoms, dystonia, akathisia, tardive dyskinesia. Interference with temperature regulation. Neuroleptic malignant syndrome. CNS effects, GI disturbances, nasal congestion, antimuscarinic symptoms, CV effects, ECG changes, endocrine effects, blood dyscrasias, photosensitisation, contact sensitisation and rashes, hepatitis and jaundice, corneal and lens opacities and purplish pigmentation of the skin, cornea, conjunctiva and retina.
Potentially Fatal: Aplastic anaemia.

Serum levels may be decreased by concurrent use with antacids containing aluminium/magnesium hydroxide and sucralfate. Increased risk of adverse effects when used with moclobemide.

Description:
Mechanism of Action: Remoxipride is an atypical antipsychotic that has high selectivity for dopamine D2-receptors. It had been used for the treatment of schizophrenia and other psychoses, but was withdrawn due to reports of aplastic anaemia; though still remain available for the treatment of refractory psychoses.

Thuốc chống loạn thần